Try our Advanced Search for more refined results

AbbVie Inc. v. Aurobindo Pharma USA, Inc. et al

  1. September 15, 2025

    AbbVie Settles Rinvoq Litigation, Blocks Generics Until 2037

    AbbVie Inc. has settled litigation with drug manufacturers, blocking generic versions of its immunosuppressant Rinvoq drug from the market for just over a decade and closing out litigation that accused generic-drug makers of infringing a slew of its patents.

  2. April 11, 2025

    AbbVie, Sandoz Settle Patent Fight Over Rinvoq Generics

    AbbVie has settled a dispute accusing Sandoz of infringing multiple patents with its proposed generic versions of AbbVie's blockbuster immunosuppressant drug Rinvoq, according to a stipulation filed Friday in Delaware federal court.

  3. November 21, 2023

    AbbVie Says Rivals' Rinvoq Generics Infringe 34 Patents

    AbbVie has lodged 136 patent infringement claims against Sandoz and a handful of other pharmaceutical companies, accusing them of infringing dozens of AbbVie's patents with their proposed generic versions of its blockbuster immunosuppressant Rinvoq, according to a suit filed in Delaware federal court.